论文部分内容阅读
目的 探讨厄贝沙坦联合活性维生素D对IgA肾病患者免疫功能及转化生长因子-β1(TGF-β1)和血清转铁蛋白受体(sTfR)表达的影响.方法 前瞻性选取2013年1月至2016年1月间的60例IgA肾病患者为研究对象,根据随机数字表法分为三组,分别为厄贝沙坦组、活性维生素D组及厄贝沙坦联合活性维生素D组,每组20例.厄贝沙坦组给予厄贝沙坦片,活性维生素D组给予骨化三醇胶丸,厄贝沙坦联合活性维生素D组给予厄贝沙坦片和骨化三醇胶丸.比较三组患者的临床疗效,治疗前后的免疫功能及TGF-β1、sTfR表达水平,观察各组不良反应情况.结果 厄贝沙坦联合活性维生素D组(90.00%)的总有效率显著高于厄贝沙坦组(75.00%)和活性维生素D组(55.00%),差异具有统计学意义(P 0.05).结论 厄贝沙坦联合活性维生素D对于治疗IgA肾病具有良好疗效,能够降低患者的尿蛋白含量,降低TGF-β1、sTfR的表达水平,改善免疫功能,值得临床推广应用.“,”Objective To discuss the effect of Irbesartan combined with activated vitamin D on immune function and expression of TGF-β1,sTfR in patients with IgA nephropathy. Methods From January 2013 to January 2016,60 patients with IgA nephropathy were selected for this study in our hospital and the patients were divided into three groups,Irbesartan group,activated vitamin D group and Irbesartan combined with activated vitamin D group,20 cases in each group. The Irbesartan group was treated with Irbesartan,activated vitamin D group was treated with activated vitamin D,and Ibesartan combined with activated vitamin D group was treated with Irbesartan combined with activated vitamin D. The curative effect,immune function and expression of TGF-β1,sTfR of three groups were compared before and after treatment. Results The total effective rate(90.00%)of Ibesartan combined with activated vitamin D group was significantly higher than Irbesartan group(75.00%)and acti-vated vitamin D group(55.00%),difference was statistically significant(P 0.05). Conclusion The application of Irbe-sartan combined with activated vitamin D is effective for the patients with IgA nephropathy and it can reduce the urine protein content,reduce the expression of TGF-β1,sTfR,improve immune function,it is worthy of clinical application.